Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 8, 2011, Pages

  Sze, Lisa ^a   Purtell, Louise ^b   Jenkins, Arthur ^b,c   Loughnan, Georgina ^d   Smith, Ellie ^e   Herzog, Herbert ^b   Sainsbury, Amanda ^b,f   Steinbeck, Katharine ^d,g   Campbell, Lesley V ^b   Viardot, Alexander ^b  

^a Division of Endocrinology and Diabetes   (Switzerland)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; EXENDIN 4; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PEPTIDE YY; PEPTIDE YY [3-36]; PLACEBO;

ADULT; AGE; APPETITE; ARTICLE; BLOATING; BODY FAT; BODY MASS; CALORIMETRY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENERGY EXPENDITURE; GENDER; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEADACHE; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; MEAL; NAUSEA; OBESITY; PILOT STUDY; POSTPRANDIAL STATE; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SATIETY; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; VISUAL ANALOG SCALE; VOMITING;

ADULT; APPETITE; BLOOD GLUCOSE; CROSS-OVER STUDIES; EATING; ENERGY METABOLISM; FEMALE; GASTROINTESTINAL HORMONES; HOMEOSTASIS; HUMANS; HUNGER; HYPOGLYCEMIC AGENTS; MALE; OBESITY; PEPTIDES; PILOT PROJECTS; PLACEBOS; PRADER-WILLI SYNDROME; SATIETY RESPONSE; TRIGLYCERIDES; VENOMS;

EID: 79961219061     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0038     Document Type: Article

References (26)

1. Burman P, Ritzén EM, Lindgren AC 2001 Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 22:787-799 (Pubitemid 34214295)
2. Holland AJ, Treasure J, Coskeran P, Dallow J 1995 Characteristics of the eating disorder in Prader-Willi syndrome: implications for treatment. J Intellect Disabil Res 39(Pt 5):373-381
3. Lindgren AC, Barkeling B, Hägg A, Ritzén EM, Marcus C, Rössner S 2000 Eating behavior in Prader-Willi syndrome, normal weight, and obese control groups. J Pediatr 137:50-55 (Pubitemid 30470922)
4. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD 2005 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091 (Pubitemid 40616617)
5. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M 2010 Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 33:1173-1175
6. Pérez-Tilve D, González-Matías L, Alvarez-Crespo M, Leiras R,Tovar S, Diéguez C, Mallo F 2007 Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 56:143-151
7. Larsen PJ, Holst JJ 2005 Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept 128:97-107 (Pubitemid 40380910)
8. Osaka T, Endo M, Yamakawa M, Inoue S 2005 Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 26: 1623-1631 (Pubitemid 41169757)
9. Pannacciulli N, Bunt JC, Koska J, Bogardus C, Krakoff J 2006 Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr 84:556-560 (Pubitemid 44713405)
10. Shalev A, Holst JJ, Keller U 1997 Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Invest 27:10-16 (Pubitemid 27065167)
11. Schuster DP, Osei K, Zipf WB 1996 Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects. Metabolism 45:1514-1520 (Pubitemid 26424580)
12. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ 1996 Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 45:633-638 (Pubitemid 26140548)
13. Hill AJ, Blundell JE 1982 Nutrients and behaviour: research strategies for the investigation of taste characteristics, food preferences, hunger sensations and eating patterns in man. J Psychiatr Res 17: 203-212 (Pubitemid 14227990)
14. Van Cauter E, Mestrez F, Sturis J, Polonsky KS 1992 Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368-377
15. Hoybye C, Barkeling B, Naslund E, Thorén M, Hellstrom PM 2007 Eating behavior and gastric emptying in adults with Prader-Willi syndrome. Ann Nutr Metab 51:264-269 (Pubitemid 47290390)
16. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L 2008 Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, noninferiority study. Lancet 372:1240-1250
17. Meier JJ, Kemmeries G, Holst JJ, Nauck MA 2005 Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54:2212-2218 (Pubitemid 40911286)
18. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo E 2008 Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol 294:E846-E852
19. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD 2003 Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082-3089 (Pubitemid 36877476)
20. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR 2001 Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol 281:E155-E161
21. Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, Wishart J, Horowitz M, Feinle-Bisset C 2006 Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 91: 1916-1923
22. Näslund E, Bogefors J, Skogar S, Grybäck P, Jacobsson H, Holst JJ, Hellström PM 1999 GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277: R910-R916 (Pubitemid 29458166)
23. Ionut V, Zheng D, Stefanovski D, Bergman RN 2008 Exenatide can reduce glucose independent of islet hormones or gastric emptying. Am J Physiol 295:E269-E277
24. Zheng D, Ionut V, Mooradian V, Stefanovski D, Bergman RN 2009 Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver. Diabetes 58:352-359
25. Brennan IM, Otto B, Feltrin KL, Meyer JH, Horowitz M, Feinle-Bisset C 2007 Intravenous CCK-8, but not GLP-1, suppresses ghrelin and stimulates PYY release in healthy men. Peptides 28:607-611 (Pubitemid 46204995)
26. Hagemann D, Holst JJ, Gethmann A, Banasch M, Schmidt WE, Meier JJ 2007 Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. Regul Pept 143:64-68 (Pubitemid 47214648)